Single-cell genomics identifies immune response to neoadjuvant chemoradiotherapy.
Single-cell genomics identifies immune response to neoadjuvant chemoradiotherapy.
复制标题
单细胞基因组学鉴定对新辅助放化疗的免疫应答。
DOI：
10.1016/j.ebiom.2022.104389
复制
发表时间：
2022-12
期刊：
影响因子：
11.1
通讯作者：
Lin DC
中科院分区：
文献类型：
--
作者：
Sinha UK;Kast WM;Lin DC
食管癌是世界上第七大常见癌症，死亡率排名第六。1食管鳞状细胞癌（ESCC）是主要亚型，其患者的5年生存率< 20%，具有高致死率。对于局部晚期、可切除的escc，通常采用术前新辅助放化疗（neoCRT）。然而，就像大多数其他癌症疗法一样，不同患者对neoCRT的临床反应差异很大，这在很大程度上是由于缺乏用于患者选择的预测性生物标志物。毫无疑问，发展基于生物标志物的精确治疗需要对neoCRT反应性的细胞机制进行高级表征和理解。肿瘤微环境是一个由多种细胞类型组成的复杂生态系统，它们共同塑造了肿瘤的生物学特性，并影响了肿瘤对治疗的敏感性。在ESCC中，多个基质细胞群与患者生存和治疗效果密切相关。3,4最近，研究人员利用单细胞RNA-Seq方法分析了ESCC肿瘤生态系统的基质异质性。3-6然而，ESCC肿瘤微环境对CRT的细胞和分子变化尚未被详细探讨。在最近一期的《电子生物医学》（eBiomedicine）杂志上，Wen等人通过对来自8个移植前和7个移植后ESCC样本的111,784个细胞进行单细胞转录组分析，解决了这个关键问题。7广泛
Esophageal carcinoma is the 7th most common cancer worldwide and has the 6th highest mortality rate. 1 As the major subtype, esophageal squamous cell carcinoma (ESCC) is highly lethal with its patients suffering a dismal five-year survival rate of< 20%. 2 For locally advanced, resectable ESCCs, preoperative neoadjuvant chemoradiotherapy (neoCRT) is commonly employed. However, just like most other cancer therapies, clinical responses to neoCRT vary substantially among patients, largely owing to the lack of predictive biomarkers for patient selection. Undoubtedly, advanced characterization and understanding of cellular mechanisms underlying the responsiveness to neoCRT is required for the development of biomarker-based precision treatment.Tumor microenvironment is a complex ecosystem of diverse cell types, together shaping cancer biology and impacting the sensitivity to therapy. In ESCC, multiple stromal cell populations correlate strongly with patient survival and therapeutic efficacy. 3, 4 Recently, the stromal heterogeneity of ESCC tumor ecosystem has been analyzed by single-cell RNA-Seq approaches. 3–6 However, cellular and molecular changes of ESCC tumor microenvironment in response to CRT have not hitherto been explored in detail. In the recent issue of eBiomedicine, Wen et al. address this critical question using single-cell transcriptomic profiling of 111,784 cells from 8 pre-and 7 post-neoCRT ESCC samples. 7 Extensive
登录
查看更多内容
影响因子：
6.2
作者：
Chen Z;Huang Y;Hu Z;Zhao M;Bian Y;Chen Z;Zheng Y;Bi G;Pang Y;Zhan C;Lin Z;Guo W;Wang Q;Tan L
通讯作者：
Tan L
术前派姆单抗联合放化疗治疗食管鳞癌（PALACE-1）
影响因子：
8.4
作者：
Li, Chengqiang;Zhao, Shengguang;Li, Hecheng
通讯作者：
Li, Hecheng
影响因子：
29.4
作者：
Lin DC;Wang MR;Koeffler HP
通讯作者：
Koeffler HP
新辅助放化疗对食管鳞癌免疫格局的影响
影响因子：
11.1
作者：
Wen, Jing;Fang, Shuogui;Hu, Yi;Xi, Mian;Weng, Zelin;Pan, Chuqing;Luo, Kongjia;Ling, Yihong;Lai, Renchun;Xie, Xiuying;Lin, Xiaodan;Lin, Ting;Chen, Jiyang;Liu, Qianwen;Fu, Jianhua;Yang, Hong
通讯作者：
Yang, Hong
人食管鳞状细胞癌微环境中的免疫抑制景观
影响因子：
16.6
作者：
Zheng Y;Chen Z;Han Y;Han L;Zou X;Zhou B;Hu R;Hao J;Bai S;Xiao H;Li WV;Bueker A;Ma Y;Xie G;Yang J;Chen S;Li H;Cao J;Shen L
通讯作者：
Shen L